此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Single Ascending Doses of BIIB063 in Healthy Volunteers

2017年4月17日 更新者:Biogen

Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy volunteers. The secondary objectives of the study are to estimate the PK parameters of single ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F) of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses of BIIB063.

研究概览

地位

终止

条件

研究类型

介入性

注册 (实际的)

29

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • West Yorkshire
      • Leeds、West Yorkshire、英国、LD2 9LH
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
  • Must have a body mass index between 18 and 30 kg/m2, inclusive.
  • Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.

Key Exclusion Criteria:

  • History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
  • History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
  • Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
  • History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
  • History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
  • Personal history of thromboembolic events
  • Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
  • Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
  • Blood donation (1 unit or more) within 3 months prior to randomization.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
单剂量
实验性的:IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
单剂量
实验性的:IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
单剂量
实验性的:IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
单剂量
实验性的:IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
单剂量
实验性的:IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
单剂量
实验性的:IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
单剂量
实验性的:SC Dose
Single SC dose or matching placebo
Single ascending IV dose
单剂量

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to week 12
Up to week 12
Number of participants with clinically significant laboratory assessment abnormalities
大体时间:Up to week 12
Up to week 12
Number of participants with clinically significant Vital sign abnormalities
大体时间:Up to week 12
Up to week 12
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
大体时间:Up to week 12
Up to week 12
Number of participants with clinically significant physical examination abnormalities
大体时间:Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for tetanus
大体时间:Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for diphtheria
大体时间:Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for pneumococcus
大体时间:Up to week 12
Up to week 12

次要结果测量

结果测量
大体时间
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
大体时间:Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
大体时间:Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
大体时间:Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
大体时间:Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
大体时间:Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
大体时间:Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
大体时间:Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
大体时间:Up to week 12
Up to week 12
Number of participants with positive serum anti-BIIB063 antibodies
大体时间:Up to week 12
Up to week 12
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
大体时间:Up to 12 weeks
Up to 12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年9月30日

初级完成 (实际的)

2016年6月1日

研究完成 (实际的)

2016年6月1日

研究注册日期

首次提交

2015年8月27日

首先提交符合 QC 标准的

2015年9月17日

首次发布 (估计)

2015年9月21日

研究记录更新

最后更新发布 (实际的)

2017年4月18日

上次提交的符合 QC 标准的更新

2017年4月17日

最后验证

2017年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • 234HV101
  • 2015-001283-18 (EudraCT编号)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅